Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.
Hope W, Johnstone G, Cicconi S, Felton T, Goodwin J, Whalley S, Santoyo-Castelazo A, Ramos-Martin V, Lestner J, Credidio L, Dane A, Carr DF, Pirmohamed M, Salim R, Neely M. Hope W, et al. Among authors: cicconi s. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02353-18. doi: 10.1128/AAC.02353-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30670416 Free PMC article.
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
Castle J, Blower E, Bundred NJ, Harvey JR, Thachil J, Marshall A, Cox K, Cicconi S, Holcombe C, Palmieri C, Kirwan CC. Castle J, et al. Among authors: cicconi s. Trials. 2020 Aug 27;21(1):749. doi: 10.1186/s13063-020-04675-7. Trials. 2020. PMID: 32854772 Free PMC article.
SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol.
McCarthy C, Sacco J, Fedele S, Ho M, Porter S, Liloglou T, Greenhalf B, Robinson M, Young B, Cicconi S, Chauhan S, Tesfaye B, Jackson R, Sherratt F, Shaw R. McCarthy C, et al. Among authors: cicconi s. Trials. 2021 Jul 5;22(1):428. doi: 10.1186/s13063-021-05373-8. Trials. 2021. PMID: 34225765 Free PMC article.
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience.
Hall BJ, Bhojwani AA, Wong H, Law A, Flint H, Ahmed E, Innes H, Cliff J, Malik Z, O'Hagan JE, Hall A, Sripadam R, Tolan S, Ali Z, Hart C, Errington D, Alam F, Giuliani R, Mehta S, Khanduri S, Thorp N, Jackson R, Cicconi S, Palmieri C. Hall BJ, et al. Among authors: cicconi s. Breast J. 2022 Jun 30;2022:7146172. doi: 10.1155/2022/7146172. eCollection 2022. Breast J. 2022. PMID: 35833190 Free PMC article.
The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool.
Olsson-Brown A, Piskilidis P, O'Hagan J, Thorp N, Robson P, Innes H, Wong H, Cicconi S, Jackson R, Kiernan T, Holcombe C, O'Reilly S, Palmieri C. Olsson-Brown A, et al. Among authors: cicconi s. Breast. 2019 Apr;44:94-100. doi: 10.1016/j.breast.2019.01.005. Epub 2019 Jan 18. Breast. 2019. PMID: 30703670
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Pettitt AR, Jackson R, Cicconi S, Polydoros F, Yap C, Dodd J, Bickerstaff M, Stackpoole M, Khan UT, Carruthers S, Oates M, Lin K, Coupland SE, Menon G, Kalakonda N, McCarthy H, Bloor A, Schuh A, Duncombe A, Dearden C, Fegan C, Kennedy B, Walewska R, Marshall S, Fox CP, Hillmen P. Pettitt AR, et al. Among authors: cicconi s. Haematologica. 2020 Dec 1;105(12):2868-2871. doi: 10.3324/haematol.2019.230805. Haematologica. 2020. PMID: 33256390 Free PMC article. No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 32054653
58 results